<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463723</url>
  </required_header>
  <id_info>
    <org_study_id>FR-2000-2003</org_study_id>
    <nct_id>NCT00463723</nct_id>
  </id_info>
  <brief_title>Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Patients following allogeneic keratoplasty are treated with topical and
      frequently with systemic steroids to prevent immune reactions. Steroids are known to yield
      good results, but exert a wide range of side effects. The efficacy of topial FK506 in
      preventing immune reactions has already been demonstrated experimentally. FK506, an
      IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent
      than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be
      compared to our standard treatment (i.e. steroids) after penetrating normal-risk
      keratoplasty.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <condition>Penetrating Keratoplasty</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK506 0.06% (eye drops)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Penetrating keratoplasty for Keratoconus

          -  Penetrating keratoplasty for Fuchs endothelial dystrophie

          -  Penetrating keratoplasty for Bullous keratopathy

        Exclusion Criteria:

          -  Glaucoma

          -  Limbal stem cell deficiency

          -  Herpetic eye disease

          -  Repeat Keratoplasty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Reinhard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University eye hospital Freiburg, Germany</affiliation>
  </overall_official>
  <results_reference>
    <citation>Reinhard T, Mayweg S, Reis A, Sundmacher R. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int. 2005 Feb;18(2):193-7.</citation>
    <PMID>15691272</PMID>
  </results_reference>
  <verification_date>August 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2007</study_first_posted>
  <last_update_submitted>April 18, 2007</last_update_submitted>
  <last_update_submitted_qc>April 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2007</last_update_posted>
  <keyword>penetrating keratoplasty</keyword>
  <keyword>graft rejection</keyword>
  <keyword>immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

